Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine

J Acquir Immune Defic Syndr. 2011 Apr;56(4):e113-5. doi: 10.1097/QAI.0b013e31820a9ae4.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Antiretroviral Therapy, Highly Active / methods
  • CD4 Lymphocyte Count
  • Cyclohexanes / administration & dosage*
  • Cyclohexanes / adverse effects
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Maraviroc
  • Middle Aged
  • Nitriles
  • Pyridazines / administration & dosage*
  • Pyridazines / adverse effects
  • Pyrimidines
  • Pyrrolidinones / administration & dosage*
  • Pyrrolidinones / adverse effects
  • RNA, Viral / blood
  • Raltegravir Potassium
  • Salvage Therapy / adverse effects*
  • Salvage Therapy / methods
  • Treatment Outcome
  • Triazoles / administration & dosage*
  • Triazoles / adverse effects
  • Viral Load

Substances

  • Anti-HIV Agents
  • Cyclohexanes
  • Nitriles
  • Pyridazines
  • Pyrimidines
  • Pyrrolidinones
  • RNA, Viral
  • Triazoles
  • etravirine
  • Raltegravir Potassium
  • Maraviroc